Trial Profile
ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Methotrexate
- Indications Breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms ABCDE
- 20 Dec 2021 Status changed from active, no longer recruiting to discontinued.
- 28 Aug 2018 Planned End Date changed from 1 Sep 2017 to 1 Jul 2019.
- 28 Aug 2018 Status changed to active, no longer recruiting.